Amgen vs SpaceX: Founders, CEOs and History
Amgen was founded in 1980 by George B. Rathmann, William K. Bowes Jr. and is led by Robert A. Bradway. SpaceX was founded in 2002 by Elon Musk and is led by Elon Musk.
Company facts
Founders
Amgen
George B. Rathmann
Amgen, originally incorporated as Applied Molecular Genetics, was founded in 1980 not by a single scientist, but by a calculated syndicate of venture capitalists and academics trying to commercialize the brand-new science of recombinant DNA.
William K. Bowes Jr.
William K. Bowes Jr. Was the venture capital strategist whose vision catalyzed Amgen's formation.
SpaceX
Elon Musk
Elon Reeve Musk was born on June 28, 1971, in Pretoria, South Africa, and emigrated to Canada at age 17 before transferring to the University of Pennsylvania, where he earned dual degrees in economics and physics.
CEOs and their tenures
Amgen
- George B. Rathmann1980–1988
Chief Executive Officer
George Rathmann, a physical chemist who had run research and development at Abbott Laboratories, was named Amgen's first chief executive in 1980 and worked from a small trailer so that laboratory space could go to scientists.
Source - Gordon M. Binder1988–2000
Chief Executive Officer
Gordon Binder joined Amgen as chief financial officer in 1982 and led its June 1983 initial public offering.
Source - Kevin W. Sharer2000–2012
Chief Executive Officer
Kevin Sharer joined Amgen in 1992 as president and chief operating officer and became chairman and chief executive in 2000.
Source - Robert A. Bradway2012–present
Chairman and Chief Executive Officer
Robert Bradway became chief executive on May 23, 2012, succeeding Kevin Sharer as the fourth CEO in Amgen's history, and added the chairmanship at the start of 2013.
Source
SpaceX
- Elon Musk2002–present
Founder, CEO & Chief Engineer
Under Musk, SpaceX became the highest-cadence launch provider and built Starlink into its largest revenue segment. He led the company through its June 12, 2026 IPO, priced at $135 per share and raising $85.7 billion.
Source - Gwynne Shotwell2002–present
President and Chief Operating Officer
As President and COO since 2008, she has managed day-to-day operations and strategic customer relationships, guiding the company to unprecedented launch cadences and billions in recurring Starlink revenues.
Source
Timeline: Amgen and SpaceX side by side
1980Amgen
Applied Molecular Genetics is incorporated
Applied Molecular Genetics (AMGen) was incorporated on April 8, 1980 in Thousand Oaks, California, as the idea of venture capitalist William K. Bowes Jr. and a group of scientific collaborators.
1983Amgen
Nasdaq listing and the erythropoietin clone
Amgen completed its initial public offering on June 17, 1983, raising nearly US$40 million under chief financial officer Gordon Binder, and formally shortened its name to Amgen.
1984Amgen
Kirin-Amgen joint venture formed
Amgen and Kirin Brewery Company of Japan formed Kirin-Amgen in 1984 as a joint venture for the worldwide commercialization of erythropoietin.
1985Amgen
G-CSF cloned, leading to Neupogen
While Fu-Kuen Lin's team worked on erythropoietin, researcher Larry Souza and his group cloned and expressed human granulocyte colony-stimulating factor in 1985.
1989Amgen
FDA approves Epogen
The FDA approved Epogen (epoetin alfa) on June 1, 1989 for anemia in patients with chronic kidney failure on dialysis. It was the first commercial recombinant human erythropoietin. Epogen's U.S.
1991Amgen
Neupogen approved, giving Amgen a second franchise
The FDA approved Neupogen (filgrastim) in February 1991. By stimulating white blood cell production it reduced the risk of infection in cancer patients with chemotherapy-induced neutropenia.
1991Amgen
Amgen wins the erythropoietin patent fight
On March 6, 1991 the U.S. Court of Appeals for the Federal Circuit upheld the Kirin-Amgen erythropoietin patent and ruled against Genetics Institute in Amgen v. Chugai Pharmaceutical and Genetics Institute.
2001Amgen
FDA approves Aranesp, the longer-acting EPO
Aranesp (darbepoetin alfa), an erythropoietin analogue with modified glycosylation and a longer half-life, was approved in 2001. Less frequent dosing than Epogen improved convenience and gave Amgen a newer, higher-priced product to migrate patients toward.
2002Amgen
US$16 billion Immunex acquisition brings Enbrel in-house
Amgen completed its acquisition of Immunex Corporation on July 16, 2002, the largest biotechnology deal to that point at about US$16 billion in stock and cash.
2002SpaceX
SpaceX is founded
Elon Musk founded Space Exploration Technologies Corp. to reduce launch costs and make Mars settlement technically possible.
2008SpaceX
Falcon 1 reaches orbit
Falcon 1 became the first privately developed liquid-fuel rocket to reach orbit, rescuing SpaceX after three failed attempts.
2010Amgen
Prolia and XGEVA create the bone health franchise
The FDA approved Prolia (denosumab) for postmenopausal osteoporosis in June 2010 and XGEVA, the same molecule at a higher dose, for prevention of skeletal-related events in cancer patients in November 2010.
2012SpaceX
Dragon reaches the ISS
Dragon became the first private spacecraft to dock with the International Space Station, proving SpaceX could serve NASA cargo missions.
2015SpaceX
Falcon 9 booster landing
SpaceX landed an orbital-class booster, establishing the technical base for reusable launch economics.
2017SpaceX
Orbital booster reflight
SpaceX reflown an orbital-class booster, pushing reuse from demonstration into operating model.
2019Amgen
US$13.4 billion purchase of Otezla from Celgene
Amgen agreed in August 2019 to buy worldwide rights to Otezla (apremilast) from Celgene for US$13.4 billion in cash, or about US$11.2 billion net of the present value of US$2.2 billion of anticipated future cash tax benefits, and closed on November 21, 2019.
2020Amgen
Amgen joins the Dow Jones Industrial Average
Amgen replaced Pfizer in the Dow Jones Industrial Average on August 31, 2020, becoming one of the thirty components in the index. Inclusion recognized the scale Amgen had reached and added passive demand from Dow-tracking funds.
2020SpaceX
Crew Dragon carries astronauts
SpaceX became the first private company to carry astronauts to orbit, restoring U.S. crew launch capability.
2021SpaceX
Acquired Swarm Technologies
SpaceX acquired Swarm Technologies.
2023Amgen
US$27.8 billion Horizon Therapeutics acquisition closes
Amgen completed the acquisition of Horizon Therapeutics plc on October 6, 2023 for US$116.50 per share in cash, an equity value of about US$27.8 billion, after settling FTC litigation with a behavioral consent decree.
2023SpaceX
Starship flight testing begins
SpaceX conducted the first integrated Starship flight test, starting the high-risk development cycle for its next launch system.
2024Amgen
Imdelltra becomes the first T-cell engager for small cell lung cancer
The FDA granted accelerated approval to tarlatamab, sold as Imdelltra, on May 16, 2024 for extensive stage small cell lung cancer that has progressed on or after platinum-based chemotherapy.
2025Amgen
VESALIUS-CV extends the Repatha case to primary prevention
In November 2025 Amgen reported Phase 3 VESALIUS-CV results in more than 12,000 patients with atherosclerosis or diabetes but no prior heart attack or stroke.
2025SpaceX
FY2025 revenue reaches $18.674B
SpaceX reported $18.674B in FY2025 revenue and a $4.937B net loss in its 2026 prospectus.
2026Amgen
Medicare price setting reaches Enbrel and Otezla
Enbrel's negotiated Medicare price under the Inflation Reduction Act took effect on January 1, 2026, after it was named in the first round of ten drugs selected for negotiation.
2026SpaceX
Prospectus lists SPCX and Starlink scale
The 2026 prospectus described a Nasdaq listing under SPCX and about 10.3M Starlink subscribers as of March 31, 2026.
Acquisitions
Amgen
- Horizon Therapeutics plc2023$27.8B
- ChemoCentryx, Inc.2022$3.7B
- Five Prime Therapeutics2021$1.9B
- Celgene Otezla Business2019$13.4B
- Onyx Pharmaceuticals, Inc.2013$10.4B
- DeCODE Genetics2012$415M
Questions about Amgen vs SpaceX
Who is the CEO of Amgen Inc. and SpaceX?
Amgen Inc. is led by Robert A. Bradway and SpaceX is led by Elon Musk. Both serve as the top executive responsible for the company's strategy, operations, and financial performance.
When was Amgen Inc. founded vs SpaceX?
Amgen Inc. was founded in 1980 — 22 years before SpaceX, which was founded in 2002. Amgen Inc.'s longer operating history gives it a deeper track record but also potentially more institutional inertia compared to the younger SpaceX.
How many employees does Amgen Inc. have compared to SpaceX?
Amgen Inc. employs approximately 31,500 people, while SpaceX employs approximately 22,621. Amgen Inc. has the larger workforce at 31,500 employees, compared to SpaceX's 22,621. A higher headcount does not necessarily imply greater efficiency — it often reflects differences in business model (e.g., manufacturing vs. software).
Where are Amgen Inc. and SpaceX headquartered?
Both Amgen Inc. and SpaceX are headquartered in United States, meaning they operate under the same primary regulatory and tax environment.
Who founded Amgen Inc. and SpaceX?
Amgen Inc. was founded by George B. Rathmann, William K. Bowes Jr.. SpaceX was founded by Elon Musk.
Which company has a longer operating history — Amgen Inc. or SpaceX?
Amgen Inc. has been operating for approximately 46 years, making it the more established of the two companies. SpaceX has been in operation for around 24 years. A longer operating history often signals greater institutional resilience and brand recognition, though it can also mean slower adaptation to new market conditions.
Figures come from each company's filings and the sources linked beside them. Amounts reported in another currency are shown in US dollars at an approximate rate and marked with ~. Back to the Amgen vs SpaceX overview